Genmab A/S Sponsored ADR $GMAB Holdings Decreased by Mirae Asset Global Investments Co. Ltd.

Mirae Asset Global Investments Co. Ltd. reduced its stake in shares of Genmab A/S Sponsored ADR (NASDAQ:GMAB) by 94.9% during the second quarter, Holdings Channel.com reports. The firm owned 1,620 shares of the company’s stock after selling 30,383 shares during the period. Mirae Asset Global Investments Co. Ltd.’s holdings in Genmab A/S were worth $33,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the business. Rhumbline Advisers raised its position in Genmab A/S by 3.2% in the first quarter. Rhumbline Advisers now owns 16,956 shares of the company’s stock worth $332,000 after acquiring an additional 532 shares in the last quarter. Park Avenue Securities LLC raised its position in Genmab A/S by 5.9% in the second quarter. Park Avenue Securities LLC now owns 14,940 shares of the company’s stock worth $309,000 after acquiring an additional 832 shares in the last quarter. Gallacher Capital Management LLC raised its position in Genmab A/S by 6.8% in the first quarter. Gallacher Capital Management LLC now owns 14,346 shares of the company’s stock worth $281,000 after acquiring an additional 915 shares in the last quarter. Eagle Global Advisors LLC increased its stake in Genmab A/S by 0.5% in the 2nd quarter. Eagle Global Advisors LLC now owns 210,295 shares of the company’s stock worth $4,345,000 after purchasing an additional 1,000 shares in the last quarter. Finally, Caitong International Asset Management Co. Ltd increased its stake in Genmab A/S by 124.3% in the 1st quarter. Caitong International Asset Management Co. Ltd now owns 1,931 shares of the company’s stock worth $38,000 after purchasing an additional 1,070 shares in the last quarter. 7.07% of the stock is currently owned by institutional investors.

Genmab A/S Price Performance

NASDAQ:GMAB opened at $31.81 on Monday. Genmab A/S Sponsored ADR has a fifty-two week low of $17.24 and a fifty-two week high of $33.63. The stock’s 50-day moving average is $26.86 and its two-hundred day moving average is $22.91. The stock has a market cap of $20.42 billion, a PE ratio of 15.98, a price-to-earnings-growth ratio of 1.79 and a beta of 0.98.

Genmab A/S (NASDAQ:GMAB) last released its earnings results on Thursday, August 7th. The company reported $0.54 earnings per share for the quarter, beating the consensus estimate of $0.39 by $0.15. Genmab A/S had a return on equity of 21.03% and a net margin of 37.53%.The company had revenue of $925.00 million for the quarter, compared to analysts’ expectations of $5.77 billion. Genmab A/S has set its FY 2025 guidance at EPS. On average, equities research analysts anticipate that Genmab A/S Sponsored ADR will post 1.45 earnings per share for the current year.

Analyst Ratings Changes

A number of equities analysts recently weighed in on GMAB shares. Wall Street Zen raised Genmab A/S from a “buy” rating to a “strong-buy” rating in a research note on Friday, September 26th. HC Wainwright lifted their price target on Genmab A/S from $36.00 to $40.00 and gave the stock a “buy” rating in a research note on Thursday, October 2nd. Zacks Research raised Genmab A/S from a “hold” rating to a “strong-buy” rating in a research note on Thursday, October 2nd. Truist Financial lifted their price target on Genmab A/S from $45.00 to $46.00 and gave the stock a “buy” rating in a research note on Tuesday, July 8th. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of Genmab A/S in a research note on Wednesday, October 8th. Two equities research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $40.80.

Genmab A/S Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.